EGRIFTA DIN 02438712
Status: Cancelled Post Market
Holder: THERATECHNOLOGIES INC
Molecule: TESAMORELIN (TESAMORELIN ACETATE)
Health Canada record
| Active ingredient(s) | TESAMORELIN (TESAMORELIN ACETATE) 1 MG |
|---|---|
| Dosage form | Kit; Powder For Solution |
| Route | Subcutaneous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | H01AC06 TESAMORELIN |
| Original market date | 23-Jun-2015 |
| Current status date | 30-Sep-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Theratechnologies Inc. — licence 102201, currently licensed, last inspection rating C (2024-08-14).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TESAMORELIN (TESAMORELIN ACETATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02423677 | EGRIFTA | THERATECHNOLOGIES INC | Powder For Solution; Kit | TESAMORELIN (TESAMORELIN ACETATE) 2 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 16731 | 2015-03-27 | Supplement to a New Drug Submission (SNDS) | NEW STRENGTH 1 MG/VIAL |